Clinical Social Workers in Conowingo, MD Accepting Medicare
8 Clinical Social Workers found. Showing 1 - 8
 Dawn Marie Gomez, MSW, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 151 Rock Springs Rd, Conowingo, MD 21918 Phone: 800-491-5369 Fax: 301-774-3678 |
Amanda Page, LCSW- C Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 49 Rock Springs Rd, Conowingo, MD 21918 Phone: 410-378-9696 Fax: 410-378-9922 |
April C Hopkins, LCSW-C Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 49 Rock Springs Rd, Conowingo, MD 21918 Phone: 410-378-9696 Fax: 410-378-9922 |
Jan Marie Brewer, LCSW-C Clinical Social Worker Medicare: May Accept Medicare Assignments Practice Location: 49 Rock Springs Rd, Conowingo, MD 21918 Phone: 410-378-9696 Fax: 410-378-9922 |
Karen Glab-bivens, LCSW-C Clinical Social Worker Medicare: May Accept Medicare Assignments Practice Location: 49 Rock Springs Rd, Conowingo, MD 21918 Phone: 410-378-9696 Fax: 410-378-9922 |
Rachel Dawn Priebe, LCSW-C Clinical Social Worker Medicare: May Accept Medicare Assignments Practice Location: 49 Rock Springs Rd, Conowingo, MD 21918 Phone: 410-378-9696 Fax: 410-378-9922 |
Sarah Reiman, LCSW-C Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 49 Rock Springs Rd, Conowingo, MD 21918 Phone: 443-731-2987 |
Jessica M Koontz-ferrera, LCSW-C Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 49 Rock Springs Rd, Conowingo, MD 21918 Phone: 410-378-9696 Fax: 410-378-9922 |
News Archive
Research: Digoxin reduces hospital admission of older, acute heart failure patients
Digoxin significantly reduces the likelihood of hospital admission due to all causes among ambulatory older patients with chronic heart failure and reduced ejection fraction, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Artificial antibody delivers nanoparticles to tumors
Antibodies that target epidermal growth factor receptor (EGFR) have proven themselves as potent anticancer drugs. Now, a team of investigators led by Shuming Nie, Ph.D., and Lily Yang, Ph.D., both at the Emory University School of Medicine and members of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, is aiming to capitalize on this targeting ability, using a modified anti-EGFR antibody to delivery nanoparticles into tumor cells.
TOWN HALL Los Angeles hosts panel discussion on H1N1 outbreak preparedness
"Hand Washing, Not Hand-Wringing: Preparing for H1N1" is the subject of a panel discussion hosted by TOWN HALL Los Angeles on Wednesday, September 23, 2009 at the National Center for the Preservation of Democracy in downtown Los Angeles.
GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer
GenVec, Inc. announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.
Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study
Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.
› Verified 5 days ago